美诺华跌2.02%，成交额1.27亿元，主力资金净流出1405.57万元

Company Overview - Meinuohua, established on February 19, 2004, and listed on April 7, 2017, is located in Ningbo, Zhejiang Province. The company specializes in the research, production, and sales of specialty raw materials (including intermediates) and finished pharmaceuticals [1][2]. Financial Performance - For the first half of 2025, Meinuohua achieved a revenue of 677 million yuan, representing a year-on-year growth of 11.42%. The net profit attributable to shareholders was 49.06 million yuan, showing a significant increase of 158.97% [2]. - Since its A-share listing, Meinuohua has distributed a total of 149 million yuan in dividends, with 50.58 million yuan distributed over the past three years [3]. Stock Performance - As of September 9, Meinuohua's stock price was 25.20 yuan per share, with a market capitalization of 5.54 billion yuan. The stock has increased by 99.05% year-to-date, but has seen a decline of 1.72% over the past five trading days and 12.10% over the past 20 days [1]. - The stock has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) six times this year, with the most recent appearance on August 28, where it recorded a net buy of -113 million yuan [1]. Shareholder Information - As of June 30, the number of shareholders for Meinuohua was 32,400, an increase of 17.14% from the previous period. The average number of circulating shares per shareholder was 6,590, a decrease of 14.63% [2]. - Notably, some institutional investors, including融通健康产业灵活配置混合A/B and 光大保德信信用添益债券A类, have exited the list of the top ten circulating shareholders [3]. Business Segments - The company's revenue composition includes 57.74% from intermediates and raw materials, 29.53% from formulations, 8.87% from CDMO (Contract Development and Manufacturing Organization), 3.52% from trade, and 0.34% from other sources [1]. Industry Classification - Meinuohua is classified under the pharmaceutical and biological industry, specifically in the chemical pharmaceutical and raw material drug sectors. It is associated with concepts such as assisted reproduction, hepatitis treatment, pet economy, raw materials, and small-cap stocks [2].